Last week the World Health Organization (WHO) also said testing of the malaria drug hydroxychloroquine as a treatment for Covid-19 patients had been halted after new data and studies showed no benefit.
Copyright 2020 The Associated Press. All Rights Reserved.
Swiss drug giant Novartis is ending its trial of malaria drug hydroxychloroquine against Covid-19 after failing to find enough participants, it said on Friday.
This content was published on
2 minutes
Keystone-SDA/Reuters/sb
Basel-based Novartis began the clinical trial in April. Some 440 hospitalised patients with the virus were expected to participate in the study.
But the pharma company said on June 19External link that it had decided to halt the trial due to “acute enrolment challenges that have made trial completion infeasible”.
Novartis’ move follows this week’s US Food and Drug Administration’s (FDA) decision to revoke emergency use authorisation for hydroxychloroquine against Covid-19 on grounds it and a related drug, chloroquine, are unlikely to help patients.
Hydroxychloroquine, also used to treat inflammatory disorders including rheumatoid arthritis and lupus, has been caught in a political debate as US President Donald Trump promoted it, even though there was no scientific evidence that it helps against the new coronavirus.
Several studies of the decades-old malaria drug including in Britain were recently halted after scientists concluded it was “useless” against COVID-19. Last week the World Health Organization halted the hydroxychloroquine arm of one of its trials.
“The recruitment challenge facing our hydroxychloroquine trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable time frame to determine the efficacy of hydroxychloroquine in treating patients with COVID-19,” Novartis said.
The pharmaceutical company said its study, so far, raised no safety issues and drew no conclusions about hydroxychloroquine’s efficacy.
Novartis had donated up to 130 million doses of hydroxychloroquine, including millions in the United States, and Chief Executive Vas Narasimhan two months ago claimed the drug was the company’s biggest hope against the new coronavirus.
Popular Stories
More
Demographics
Flat-hunting in Switzerland’s cheapest and most expensive municipalities
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
Swiss politicians concerned by cut to Lausanne-Paris TGV services
This content was published on
The Vaud cantonal parliament wants to maintain six direct daily TGV high-speed train services between Lausanne and Paris.
This content was published on
Switzerland and Norway have signed a bilateral agreement for the future storage of carbon dioxide (CO2) under the North Sea.
Switzerland must better protect whistleblowers, says OECD
This content was published on
Switzerland must step up its anti-corruption efforts and provide better protection for whistleblowers while increasing fines for guilty firms, an OECD anti-bribery group says.
Art Basel 2025 registers numerous million-dollar sales on first day
This content was published on
Galleries at the prestigious Art Basel fair in Switzerland have registered numerous million-dollar sales on the first preview day on June 17.
Trust in Swiss news is rising, Reuters report shows
This content was published on
Trust in the news has increased in Switzerland, according to the Reuters Institute Digital News Report 2025. Almost half (46%) of adults who took part in a recent survey said they generally trusted Swiss news, up 5%.
Five Swiss diplomats leave Tehran as Israel-Iran war enters sixth day
This content was published on
Five Swiss diplomats left the Iranian capital with their families by land by their own means on Tuesday, a Swiss foreign ministry spokesperson has confirmed.
Ex-employee of Bank Pictet convicted of money laundering
This content was published on
The Geneva-based bank Pictet has been fined CHF2 million for shortcomings in its organisation which enabled a former asset manager to commit serious money laundering.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19 is both threat and opportunity for Swiss biotech
This content was published on
Although the coronavirus pandemic is the Swiss biotech industry’s time to shine, it has left many smaller firms struggling to survive.
Hydroxychloroquine study withdrawn over data concerns
This content was published on
Authors have withdrawn an influential article finding that hydroxychloroquine had no benefit against Covid-19, citing data concerns.
Novartis CEO warns that data on Covid-19 drugs is missing
This content was published on
Potential pharmaceutical solutions to combat Covid-19 must have strong clinical data to back their efficacy, according to Novartis boss Vasant Narasimhan.
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.